Phaseline

Targets › B7H3

B7H3 (CD276 antigen): drug programs, companies and trials

31 programs from 28 companies in 69 trials: 51 Phase 1, 12 Phase 3, 6 Phase 2; Oncology; next expected readout Dec 2026.

May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. (UniProt, Q5ZPR3)

Open in Phaseline: the race on B7H3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Qilu PharmaceuticalQLC5508
B7H3-targeting antibody-drug conjugate
B7H3Phase 3Esophageal Squamous Cell Carcinoma (ESCC); Extensive-stage Small Cell Lung Cancer; Refractory or Relapsed Solid Tumors; Advanced Prostate Cancer …Dec 2026
Daiichi SankyoIfinatamab deruxtecan (DS-7300a, I-DXd)
Anti-B7H3 antibody-drug conjugate
B7H3, DLL3Phase 3Small Cell Lung Cancer; Esophageal Squamous Cell Carcinoma; Extensive-stage Small-cell Lung Cancer; Advanced Solid Tumor …Dec 2026
Hansoh BioMedical R&D CompanyHS-20093
anti-B7-H3 antibody-drug conjugate
B7H3, CD276Phase 3Osteosarcoma; Small Cell Lung Cancer; Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma …Dec 2026
MediLink Therapeutics (Suzhou)YL201
B7H3-targeting antibody-drug conjugate
B7H3Phase 3Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Advanced Esophageal Squamous Cell Carcinoma; SCLC, Extensive Stage …Jan 2027
CSPC Megalith BiopharmaceuticalSYS6043
B7-H3-targeted antibody-drug conjugate
B7H3Phase 3Platinum-resistant Ovarian Cancer; Advanced/Metastatic Solid TumorsDec 2027
BioNTech SEBNT324
B7-H3 antibody-drug conjugate
B7H3Phase 3Metastatic Castration-resistant Prostate Cancer; Advanced Lung CancerSep 2028
University College, LondonhBRCA84D CAR T cells
CAR-T cells targeting B7-H3
B7H3, GD2Phase 1Neuroblastoma; Diffuse Midline Glioma, H3 K27M-Mutant; SarcomaDec 2026
Phrontline BiopharmaTJ101
EGFR/B7H3-directed antibody-drug conjugate with cleavable linker and novel topoisomerase I
EGFR, B7H3Phase 1Lung Cancer (NSCLC)Dec 2026
Peking University People's HospitalB7H3-IRDye800CW
Anti-B7H3 antibody conjugated to IRDye800CW fluorophore for near-infrared imaging of B7-H3
B7H3Phase 1OsteosarcomaDec 2026
The Affiliated Hospital of Xuzhou Medical UniversityfhB7H3.CAR-Ts
B7H3-targeting chimeric antigen receptor T cells
B7H3Phase 1Hepatocellular CarcinomaFeb 2027
St. Jude Children's Research HospitalB7-H3-CAR T Cells
B7-H3-targeted chimeric antigen receptor T cell therapy
B7H3Phase 1Pediatric Solid Tumor; Central Nervous System Neoplasms; SarcomaMar 2027
Seattle Children's HospitalSCRI-CARB7H3(s)
B7H3-specific chimeric antigen receptor (CAR) T cell
B7H3Phase 1Central Nervous System TumorMay 2027
TcelltechTX103
Anti-B7-H3 chimeric antigen receptor T-cell (CAR-T cell) therapy
B7H3Phase 1High-grade Glioma; Solid TumorsJun 2027
IDEAYA BiosciencesIDE034
Bispecific antibody targeting B7-H3 and PTK7
B7H3, PTK7Phase 1Esophageal Squamous Cell CarcinomaJul 2027
Sun Yat-Sen University Cancer CenterGD2/B7H3 CAR-T cell therapy
Dual-targeted CAR-T cells recognizing GD2 and B7H3 antigens
GYPC, B7H3Phase 1Neuroblastoma (NB)Dec 2027
Radiopharm Theranostics177Lu-BetaBart
Lutetium-177 labeled anti-B7-H3 monoclonal antibody
B7H3Phase 1Castration-Resistant Prostate Cancer (CRPC)Dec 2027
Dushu Lake Hospital Affiliated to Soochow UniversityAllogeneic B7-H3 CAR-γδT cell (QH104)
B7-H3-targeted CAR-γδT cell therapy
B7H3Phase 1Brain GliomasDec 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineEPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy
Bispecific CAR-T cell therapy targeting B7H3 and IL13Ra2
B7H3, IL13RA2Phase 1Refractory GlioblastomaDec 2027
Eastern Hepatobiliary Surgery HospitalSuper Hi-TCR-T cells
Multi-target TCR-engineered T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP
PVRL4, KLRC1, TROP2, B7H3, GPC3Phase 1Advanced Hepatocellular Carcinoma (HCC)Jan 2028
UNC Lineberger Comprehensive Cancer CenteriC9-CAR.B7-H3 T cell infusion
Chimeric antigen receptor T cells targeting B7-H3
B7H3Phase 1Pancreas Cancer; Epithelial Ovarian CancerApr 2028
UNC Lineberger Comprehensive Cancer CenteriC9-CAR.B7-H3 T cells
CAR-T cells targeting B7-H3 antigen
B7H3Phase 1Breast Cancer; Ovary NeoplasmMay 2028
Aktis Oncology[64Cu]Cu-AKY-2519
anti-B7-H3 targeted imaging agent (copper-64 PET tracer)
B7H3Phase 1NSCLCDec 2028
NEOK BioNEOK001
B7-H3 and ROR1 targeting bispecific antibody-drug conjugate
B7H3, ROR1Phase 1Locally Advanced (Unresectable) or Metastatic Solid TumorsJan 2029
Suzhou Maximum Bio-techMT027
B7H3-specific CAR-T cells
B7H3Phase 1Advanced Malignant Solid TumorFeb 2029
Conjupro BiotherapeuticsSYS6043
Anti-B7-H3 antibody-drug conjugate
B7H3Phase 1CancerDec 2029
BioNTech SEanti-B7-H3 antibody conjugated to topoisomerase I inhibitor
anti-B7-H3 antibody-drug conjugate with topoisomerase I inhibitor
B7H3Phase 1Non-Small Cell Lung CancerFeb 2030
Masonic Cancer Center, University of MinnesotaGTB-5550
B7-H3-targeted natural killer cell engager (TriSpecific Killer Engager, TriKE)
B7H3Phase 1Tri-specific Killer EngagerJan 2031
PersonGen BioTherapeutics (Suzhou)TAA06 Injection
B7-H3-targeted CAR-T cell therapy
B7H3Phase 1B7-H3-positive Relapsed/ Refractory NeuroblastomaFeb 2039
Seattle Children's Hospitalsecond generation 4-1BBζ B7H3-EGFRt-DHFR
Dual-targeted CAR T cell therapy directed at B7H3 and CD19 with 4-1BB costimulatory domain
B7H3, CD19Phase 1Pediatric Solid TumorDec 2040
Children's National Research InstituteB7-H3 CAR T cells
B7-H3-targeting CAR T cells
B7H3Phase 1RhabdomyosarcomaDec 2041
Chulalongkorn UniversityB7H3 specific CAR T cell with IL-7Ra signaling domain
Anti-B7H3 CAR-T cell therapy with IL-7 receptor alpha co-stimulatory signaling domain
B7H3, IL7RAPhase 1DIPG Brain Tumor–

Conditions

Advanced Solid Tumor (6) Osteosarcoma (3) Small Cell Lung Cancer (3) Pediatric Solid Tumor (3) Non-Small Cell Lung Cancer (2) Advanced Solid Tumors (2) Advanced Prostate Cancer (2) Esophageal Squamous Cell Carcinoma (2) Sarcoma (2) Head and Neck Squamous Cell Carcinoma (1) Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (1) Metastatic Colorectal Cancer (CRC) (1)

Modalities

other (12), small molecule (11), mixed (5), antibody (3)

Companies

UNC Lineberger Comprehensive Cancer Center (2) Seattle Children's Hospital (2) BioNTech SE (2) Hansoh BioMedical R&D Company (1) Daiichi Sankyo (1) Qilu Pharmaceutical (1) St. Jude Children's Research Hospital (1) IDEAYA Biosciences (1) The Affiliated Hospital of Xuzhou Medical University (1) Chulalongkorn University (1) Masonic Cancer Center, University of Minnesota (1) MediLink Therapeutics (Suzhou) (1) CSPC Megalith Biopharmaceutical (1) University College, London (1) Phrontline Biopharma (1) Aktis Oncology (1) NEOK Bio (1) Peking University People's Hospital (1) Dushu Lake Hospital Affiliated to Soochow University (1) Conjupro Biotherapeutics (1)

Related targets

CD276 (1) DLL3 (1) PTK7 (1) IL7RA (1) GD2 (1) EGFR (1) ROR1 (1) CD19 (1) IL13RA2 (1) PVRL4 (1) KLRC1 (1) TROP2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.